Ph.D in Human Biology, (Summa cum laude), 2006.
Ludwig - Maximilians – University (LMU), Munich, Germany
Blood Cancer, Normal Stem Cell and Cancer Stem Cell and Hematopoiesis
- Genetics, Epigenetics, Homeobox Genes and Small non-coding RNA
- Establishing in vitro assays and in vivo cancer models (syngeneic and xenograft) for cancer initiation, development and drug screening
- Gene knockdown or knockout in cancer cell lines and primary samples using lentivirus based shRNA or CRISPR/CAS9 methods
Jan, 2007- Aug, 2009 Junior group leader, Clinical Co-operative Group (CCG) Leukemia, Klinikum Grosshadern, LMU, Munich, Germany.
Sept, 2009 - May, 2010 Junior group leader, Institute of Experimental Cancer Research, Comprehensive Cancer Center Ulm (CCCU), University Hospital Ulm, Germany
June, 2010 – May 2016 Assistant Professor, University of Ulm, Comprehensive Cancer Center Ulm (CCCU), Germany.
July, 2016 – June 2020 Senior Scientist, Institute of Experimental Cancer Research, Comprehensive Cancer Center Ulm (CCCU), University Hospital Ulm, Germany
July, 2020 – Dec 2020 Principal Scientist, Institute of Experimental Cancer Research, Comprehensive Cancer Center Ulm (CCCU), University Hospital Ulm, Germany
Jan 2021 – till date Associate Professor, at the Special Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi-110067
Young Master Award, German/Swiss/Austrian Society of Hematology and Oncology (DGHO/SGH/ASHO), Basel, Switzerland, 2003
Selected for Young Investigator Award, International Society for Experimental Hematology (ISEH), New Orleans, USA, 2004
Best Thesis Award, Helmholtz Center Munich for Environmental & Health, Munich. Germany, 2008
Travel Award, American Society of Hematology (ASH), USA, 2003, 2006 and 2007. ISEH travel award, Melbourne, Australia, 2010.
Young investigator award, International Conference on Stem Cells and Cancer, New Delhi, India, 2012
Prof. Dr. med. Christian Buske, Director, Institute of Experimental Cancer Research, Albert-Einstein-Allee 11, 89081 Ulm, Germany
Prof. Dr. med. Michaela Feuring, Department of Internal Medicine III, Ulm University, Albert-EinsteinAllee 23, 89081 Ulm, Germany
- Bamezai S, Pulikkottil AJ, Yadav T, Naidu VM, Mueller J, Mark J, Mandal T, Feder KA, Lehle S, Song C, Rosler R, Wiese S, Hoell JI, Kloetgen A, Karsan A, Kumari A, Wojenski L, Sinha AU, Gonzalez-Menendez I, Quintanilla-Martinez L, Donato E, Trumpp A, Kruse E, Hamperl S, Zou L, Rawat VPS *, Buske C*. A non-canonical enzymatic function of PIWIL4 maintains genomic integrity and leukemic growth in AML. Blood, 6;142(1):90-105. July 2023. (IF: 25)
- Pulikkottil AJ Bamezai S, Ammer T, Mohr F, Feder K, Vegi NM, Mandal T, Kohlhofer U, Quintanilla-Martínez L, Singh A, Buske C*, Rawat VPS*. TET3 promotes AML growth and epigenetically regulates glucose metabolism and leukemic stem cell associated pathways. Leukemia, Aug. 2021.
- Bamezai S, Demir D, Pulikkottil A, Ciccarone F, Fischbein E, Sinha A, Borga C, Kronnie Gt, Meyer LH, Mohr F, Götze M, Caiafa P, Debatin KM, Döhner K, Döhner H, Menendez I, Quintanilla-Martínez L, Herold T, Jeremias I, Feuring-Buske M, Buske C*, Rawat VPS*. TET1 acts as pro-leukemic factor in human T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition. Leukemia,;35(2):389-403, Feb. 2021.
- Rawat VPS*≠, Götze M≠, Rasalkar A, Vegi NM, Ihme S, Thoene S, Pastore A, Bararia D, Döhner H, Döhner K, Feuring-Buske M, Quintanilla-Fend L, Buske C*. The microRNA miR-196b acts as tumor suppressor in Cdx2 driven acute myeloid leukemia. Haematologica.;105(6):e285-e289 Jun. 2020
- Thoene S, Mandal T, Vegi NM, Quintanilla-Martinez L, Rösler R, Wiese S, Metzeler KH, Herold T, Haferlach T, Döhner K, Döhner H, Schwarzmüller L, Klingmüller U, Buske C, Rawat VPS*, Feuring-Buske M*. The ParaHox gene Cdx4 induces acute erythroid leukemia in mice. Blood Adv. 26;3(22):3729-3739Nov. 2019
- Rawat VPS*, Arseni N*, Farid A Mulaw MA, Thoene S, Heilmeier B, Sadlon T, D’Andrea RJ, Bohlander SK, Hiddemann W, Buske C, Feuring-Buske M. The Vent-like homeobox gene VENTX promotes human myeloid development in vitro and in vivo and is highly expressed in acute myeloid leukemia. PNAS, 28;107(39):16946-51, Sep. 2010
- Rawat VPS*, Thoene S*, Heilmeier B, Hoster E, Metzeler K., Herold T, Hiddemann W, Gökbuget N. Hoelzer D. Bohlander SK, Feuring-Buske M, Buske C. The homeobox gene CDX2 is aberrantly expressed and associated with an inferior prognosis in patients with acute lymphoblastic leukemia. Leukemia,;23(4):649-55 Apr. 2009
- Rawat VP, Thoene S, Naidu V, Arseni N., Heilmeier B, Metzeler K, Petropoulos K, Deshpande AJ, Bohlander SK, Quintanilla-Martinez L, Spiekermann K, Hiddemann W, Feuring-Buske M, Buske C. Overexpression of CDX2 perturbs HOX gene expression in murine progenitors depending on its N-terminal domain and is closely correlated with deregulated HOX gene expression in human acute myeloid leukemia. Blood, 1;111(1):309-19 Jan. 2008
- Deshpande AJ, Cusan M, Rawat VP, Reuter H, Krause A, Pott C, Quintanilla-Martinez L, Kakadia P, Kuchenbauer F, Ahmed F, Delabesse E, Hahn M, Lichter P, Kneba M, Hiddemann W, Macintyre E, Mecucci C, Ludwig WD, Humphries RK, Bohlander SK, Feuring-Buske M, Buske C. Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell,;10(5):363-74. Nov. 2006
- Rawat VP, Cusan M, Deshpande A, Hiddemann W, Quintanilla-Fend L, Humphries RK, Bohlander SK, Feuring-Buske M, Buske C. Ectopic expression of the homeobox gene Cdx2 is the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia. PNAS, 101:817-822. 2004
Total Published Research Articles in International Journals: 23
Published Abstracts in International Journals: 36